Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 01:30 ET | Source: SERB Pharmaceuticals

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

SERB Pharmaceuticals to acquire development and commercialisation rights to Idefirix® (imlifidase) in Europe and MENA from Hansa Biopharma for €115 million
May 18, 2026 18:28 ET | Source: Front Porch Communities and Services

Star Room at Vista del Monte honored for Best Practice/Innovation of the Year

Santa Barbara, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- The Star Room at Vista del Monte, a Front Porch senior living community in Santa Barbara, has been named the Best Practice/Innovation of the...
May 18, 2026 17:26 ET | Source: Scripps Health

New Lusardi Tower Opens to Patients This Week At Scripps Memorial Hospital Encinitas

Encinitas, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Scripps Health today announced the upcoming opening of the Lusardi Tower, which is part of a nine-phase major expansion of the Scripps Memorial...
May 18, 2026 17:08 ET | Source: ATI Advisory

ATI Advisory Launches Public Dashboard on C-SNPs and Eligible Populations

Washington, DC, May 18, 2026 (GLOBE NEWSWIRE) -- High-performing Chronic Condition Special Needs Plans (C-SNPs) require precise population targeting, provider alignment, and operational...
May 18, 2026 17:00 ET | Source: Telix Pharmaceuticals Limited

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.Maximum dose reached with no dose-limiting toxicities observed.TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT,...
May 18, 2026 17:00 ET | Source: Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact...
May 18, 2026 16:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with...
May 18, 2026 16:17 ET | Source: PsyMetrics

PsyMetrics Releases Healthcare Workforce Benchmark Showing Up to 67% Reduction in Hospital Staff Turnover

Miami, FL, May 18, 2026 (GLOBE NEWSWIRE) -- PsyMetrics, an AI-powered psychometric assessment platform, announced the release of a healthcare workforce benchmark highlighting the long-term efficacy...
May 18, 2026 16:05 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
May 18, 2026 16:05 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) --...